CAJ | 학술논문

抗病毒疗法是治疗慢性乙型肝炎的关键.核苷类药物单独或者联合抗病毒,对HBeAg阳性或是阴性的慢性乙型肝炎患者均显示有病毒学、生化学和组织学的益处,但在长期应用中产生不同的抗药性,限制了其临床应用.此文就核苷类药物单独和联合治疗慢性乙型肝炎的现状进行概述.
항병독요법시치료만성을형간염적관건.핵감류약물단독혹자연합항병독,대HBeAg양성혹시음성적만성을형간염환자균현시유병독학、생화학화조직학적익처,단재장기응용중산생불동적항약성,한제료기림상응용.차문취핵감류약물단독화연합치료만성을형간염적현상진행개술.
Antiviral therapy is regarded as the key of chronic hepatitis B treatment. In terms of virology, biochemics and histology, no matter nucleoside/nucleotide analogues are used in monotherapy or combination therapy, these medicines can benefit all the patients, whose HBeAg are positive or negative. However, the drug-resistance occurs frequently in the long-term application, limiting its clinic effects. This thesis aims to give general introduction of the current status of chronic hepatitis B treatment with nucleoside/nucleotide analogues by monotherapy and combination therapy.